Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system

Journal of Neurochemistry

Volumn 109, Issue 3, 2009, Pages 838-845

  McFarland, Nikolaus R ^a,b   Lee, Jeng Shin ^c   Hyman, Bradley T ^b   McLean, Pamela J ^b  

^a Building 114 ^*  (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adeno associated virus; Gene therapy; Parkinson disease; Striatum; Substantia nigra; Transduction

Indexed keywords

PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSDUCTION; GLOBUS PALLIDUS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SEROTYPE; VIRUS CAPSID;

ADENOVIRIDAE; ANIMALS; GENE EXPRESSION; GENETIC VECTORS; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEINS; INFLAMMATION; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINATION, GENETIC; SEROTYPING; SUBSTANTIA NIGRA; TRANSDUCTION, GENETIC; TYROSINE 3-MONOOXYGENASE;

ADENO-ASSOCIATED VIRUS; MIRIDAE; RATTUS;

EID: 64149106830     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06010.x     Document Type: Article

References (31)

1. Broekman M. L., Comer L. A., Hyman B. T. Sena-Esteves M. (2006) Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 138, 501 510.
2. Burger C., Gorbatyuk O. S., Velardo M. J., Peden C. S., Williams P., Zolotukhin S., Reier P. J., Mandel R. J. Muzyczka N. (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10, 302 317.
3. Burger C., Nash K. Mandel R. J. (2005) Recombinant adeno-associated viral vectors in the nervous system. Hum. Gene Ther. 16, 781 791.
4. Davidson B. L., Stein C. S., Heth J. A., Martins I., Kotin R. M., Derksen T. A., Zabner J., Ghodsi A. Chiorini J. A. (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl Acad. Sci. USA 97, 3428 3432.
5. Donello J. E., Loeb J. E. Hope T. J. (1998) Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J. Virol. 72, 5085.
6. Erles K., Sebokova P. Schlehofer J. R. (1999) Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 59, 406 411.
7. Gao G., Vandenberghe L. H. Wilson J. M. (2005) New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285 297.
8. Hildinger M., Auricchio A., Gao G., Wang L., Chirmule N. Wilson J. M. (2001) Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J. Virol. 75, 6199 6203.
9. Hoglinger G. U., Oertel W. H. Hirsch E. C. (2006) The rotenone model of parkinsonism - the five years inspection. J. Neural Transm. Suppl., 70, 269 272.
10. Howard D. B., Powers K., Wang Y. Harvey B. K. (2007) Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro. Virology. 372, 24 34.
11. Jenner P., Rupniak N. M., Rose S., Kelly E., Kilpatrick G., Lees A. Marsden C. D. (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 50, 85 90.
12. Kirik D. Bjorklund A. (2003) Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci. 26, 386 392.
13. Kirik D., Rosenblad C. Bjorklund A. (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152, 259 277.
14. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., Mandel R. J. Bjorklund A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780.
15. Klein R. L., King M. A., Hamby M. E. Meyer E. M. (2002) Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13, 605 612.
16. Klein R. L., Dayton R. D., Leidenheimer N. J., Jansen K., Golde T. E. Zweig R. M. (2006) Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol. Ther. 13, 517 527.
17. Lee V. M. Trojanowski J. Q. (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 33.
18. Lo Bianco C., Ridet J. L., Schneider B. L., Deglon N. Aebischer P. (2002) Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl Acad. Sci. USA 99, 10813.
19. McCown T. J. (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther. 5, 333 338.
20. Niwa H., Yamamura K. Miyazaki J. (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193 199.
21. Paterna J. C., Feldon J. Bueler H. (2004) Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J. Virol. 78, 6808 6817.
22. Rabinowitz J. E. Samulski J. (1998) Adeno-associated virus expression systems for gene transfer. Curr. Opin. Biotechnol. 9, 470 475.
23. Rabinowitz J. E., Rolling F., Li C., Conrath H., Xiao W., Xiao X. Samulski R. J. (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791 801.
24. Reimsnider S., Manfredsson F. P., Muzyczka N. Mandel R. J. (2007) Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol. Ther. 15, 1504 1511.
25. St Martin J. L., Klucken J., Outeiro T. F. et al. (2007) Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J. Neurochem. 100, 1449 1457.
26. Taymans J. M., Vandenberghe L. H., Haute C. V., Thiry I., Deroose C. M., Mortelmans L., Wilson J. M., Debyser Z. Baekelandt V. (2007) Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. 18, 195 206.
27. Tenenbaum L., Chtarto A., Lehtonen E., Velu T., Brotchi J. Levivier M. (2004) Recombinant AAV-mediated gene delivery to the central nervous system. J. Gene Med. 6 (Suppl. 1 S212 S222.
28. Thiruchelvam M., Brockel B. J., Richfield E. K., Baggs R. B. Cory-Slechta D. A. (2000) Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res. 873, 225 234.
29. Ulusoy A., Bjorklund T., Hermening S. Kirik D. (2008) In vivo gene delivery for development of mammalian models for Parkinson's disease. Exp. Neurol. 209, 89 100.
30. West M. J., Slomianka L. Gundersen H. J. (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231, 482.
31. Wu Z., Asokan A. Samulski R. J. (2006) Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14, 316 327.